24 Hrs
Source:
The New York Times
_1777370193195_831968492.png&w=48&q=75){kind=small}
_1777370220974_847775619.png&w=48&q=75){kind=small}
Investors Watch Novo Nordisk's Outlook
Novo Nordisk’s CEO, Mike Doustdar, states that investors continue to underestimate the potential of the company's medications, amid his first year leading a corporate turnaround.
Size: 120%Text Size
Notice: This Is an AI-Generated Summary
Comments (0)